Clinical Trials Logo
  1. Home
  2. Newly Diagnosed Multiple Myeloma
  3. NCT01809717

Multiple Myeloma and Exercise

Newly Diagnosed Multiple Myeloma Clinical Trial

Official title:
Modulating The Toxicity And Efficacy Of High Dose Chemotherapy For Multiple Myeloma Through An Intervention To Increase Lean Body Mass

Clinical Trial Summary

This study will establich the feasibility of weight lifting exercise among patients with multiple myeloma, determine if weight lifting exercise increases lean body mass among patients with multiple myeloma and obtain further preliminary data on toxicity and pharmacokinetics of high-dose melphalan.

Clinical Trial Description

This is a prospective, single-institution, pilot study of a 3 month weight lifting program designed to increase musle hypertrophy prior to starting stem cell collection and receiving high-dose melphalan, in patients with multiple myeloma. We will use this exercise intervention while patients are receiving initial induction chemotherapy in the 3-6 month period before they receiv high-dose melphalan. The primary study endpoint is to determine the feasibility of recruiting and retaining multiple myeloma patients to an exercise intervention trial. The secondary study endpoint is to determine whether the weight lifting program increases lean body mass as intended. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01809717
Study type Interventional
Source Abramson Cancer Center of the University of Pennsylvania
Contact
Status Completed
Phase N/A
Start date March 2013
Completion date August 2013
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04052880 - Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM Phase 2
Active, not recruiting NCT03742297 - Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years Phase 3
Not yet recruiting NCT05558319 - NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide Phase 3
Recruiting NCT04891809 - Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM Phase 2
Not yet recruiting NCT05561049 - Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma
Completed NCT01936532 - Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06) Phase 2
Recruiting NCT05259553 - Biomarkers in Multiple Myeloma N/A
Withdrawn NCT04348006 - Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients Phase 4
Terminated NCT03733691 - Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients Phase 2
Active, not recruiting NCT00405756 - A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. Phase 3
Recruiting NCT05665140 - Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients Phase 2/Phase 3
Not yet recruiting NCT05088330 - A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM N/A
Active, not recruiting NCT03948035 - Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM Phase 3
Not yet recruiting NCT06348147 - Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation Phase 2
Recruiting NCT06324266 - Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation Phase 2/Phase 3